Early clinical and microbiological responses in the treatment of bacterial conjunctivitis with moxifloxacin ophthalmic solution 0.5% (Vigamox™) using B.I.D. dosing

Today's Therapeutic Trends

Volumn 21, Issue 2, 2003, Pages 227-237

  Gross, Robert D ^a   Lichtenstein, Steven J ^b   Schlech, Barry A ^c   Gower, Linda A ^c   Potts, Susan L ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b University of Louisville School of Medicine   (United States)

^c ALCON RESEARCH LTD   (United States)

Author keywords

B.I.D.; Bacterial conjunctivitis; Clinical study; Clinical success; Clinical utility; Microbiological success; Moxifloxacin; Therapeutic improvement; Treatment failures; Vigamox

Indexed keywords

CIPROFLOXACIN; EYE DROPS; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; QUINOLONE;

ADOLESCENT; ADULT; AGED; BACTERIAL INFECTION; CHILD; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0041942599     PISSN: 07412320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Gigliotti F, Hendly JO, Morgan J, et al.: Efficacy of topical antibiotic therapy in acute conjunctivitis in children. J. Pediatr. 104:623-626, 1984.
2. Fisher MC: Conjunctivitis in children. Pediatr. Clin. North Am. 34:1447-1456, 1987.
3. Gross RD, Hoffman RO and Lindsay RN: A comparison of ciprofloxacin and tobramycin in bacterial conjunctivitis in children. Clin. Pediatr. 36(8):435-444, 1997.
4. Ichijima H, Petroll WM, Jester JV and Cavanagh HD: Confocal microscopic studies of living rabbit cornea treated with benzalkonium chloride. Cornea 11:221-225, 1992.
5. Tripathi BJ, Tripathi RC and Kolli SP: Cytotoxicity of ophthalmic preservatives on human corneal epithelium. Lens Eye Toxic. Res. 9:361-375, 1992.
6. Schmitz FJ, Higgins PG, Mayer G, et al.: Activity of quinolones against Gram-positive cocci: Mechanisms of drug action and bacterial resistance. Eur. J. Clin. Microbiol. Infect. Dis. 21:647-659, 2002.
7. Blondeau JM: A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new 'respiratory quinolones'. J. Antimicrob. Chemother. 43(Suppl. B):1-11, 1999.
8. Dalhoff A, Petersen U and Endermann R: In vitro activity of Bay 12-8039, a new 8-methoxyquinolone. Chemotherapy 42:410-425, 1996.
9. Tankovic J, Bachoual R, Ouabdesselam S, et al.: In vitro activity of moxifloxacin against fluoroquinolone-resistant strains of aerobic gram-negative bacilli and Enterococcus faecalis. J. Antimicrob. Chemother. 43:19-23, 1999.
10. Schedletzky H, Wiedemann B and Heisig P: The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus. J. Antimicrob. Chemother. 43(Suppl. B):31-37, 1999.
11. Brueggemann AB, Coffman SL, Rhomberg P, et al.: Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob. Agents Chemother. 46:680-688, 2002.
12. Saito H: Comparative antimycobacterial activity of BAY 12-8039 and gatifloxacin. Drugs 58(Suppl. 2):400-401, 1999.
13. Block SL, Hedrick J, Tyler R, et al.: Increasing bacterial resistance in pediatric acute conjunctivitis (1997-1998). Antimicrob. Agents Chemother. 44:1650-1654, 2000.